web analytics
October 23, 2014 / 29 Tishri, 5775
At a Glance
InDepth
Sponsored Post
Meir Panim with Soldiers 5774 Roundup: Year of Relief and Service for Israel’s Needy

Meir Panim implements programs that serve Israel’s neediest populations with respect and dignity. Meir Panim also coordinated care packages for families in the South during the Gaza War.



The Israeli Dash to the NASDAQ

Shmuel Zysman

Shmuel Zysman
Photo Credit: Ranit Nachum-Halevi

“Nonetheless, people need to remember that investors are aware of all of these preliminary stages, and they set an investment goal which is right for them, especially when it comes to Israeli companies,” he said. “As I mentioned before, this is due to the relatively low price in which they offer their initial stock. On the one hand, the investors understand the risks that are on the table. On the other hand, they are aware that if the company’s IPO is valued at between $100-200 million, and if they develop a successful drug that is approved by the Food and Drug Administration, it will be worth billions of dollars, perhaps more.”

“For the investor, that means a potential profit of ten times the investment, perhaps more,” he said. “That is why he takes the risk. The stock markets of the world offer assistance to high-risk companies, and if the company comes fraught with risk, my opinion is that it is preferable if that company deals in bio-tech because it’s a win-win situation. Everybody gains. If these companies succeed, the entire globe would benefit, with the development of a product and from a financial standpoint, with investors and the stock market benefiting. If the company fails, at least science will take a step forward, and there’s no doubt that mistakes are to be learned from. In my view, this is also a gain from a social standpoint.”

What is the rate of success for Israeli biomed companies as opposed to foreign biomed companies?

“When you look at the statistics of success, you need to look at two main things: Do the Israeli companies produce a product that competes with other companies or not? I don’t know of such a statistic, but from this standpoint I don’t believe there’s much of a gap. Another marker that defines success is the profit made by the investors. At least in the first wave of IPOs, it was easy to notice that the price of Israeli companies was climbing higher, which is something that was perceived as an economic success and which produced great returns for investors. Once money comes into the coffers of a company and it could continue to develop its product, there’s no doubt that it makes the value of the company higher.”

What considerations come into play when choosing the investors and the backers? Does it have anything to do with being on the NASDAQ? Is it any different than the IPO in London? Do the funds come from private investors and funds?

“The world of biotech needs a lot of money. The capital market in every country needs a tremendous amount of money in order to try and help. In the last 10 years, the amount of institutional money and funding from risk-management funds has dropped significantly. This is a worrying fact that should be a warning sign over the state of the market, and this could endanger scientific development. The repercussions of this are global. So all of the critics who are complaining that the biomed companies are “rushing to get their shares traded on the stock exchange” are expressing criticism that is unfounded, because the capital market is one of the few existing solutions today for these companies, enabling them to continue with research and development. It’s not a question of being an alternative. Today, it’s the only alternative. As for stock markets, the best stock market is the NASDAQ. The market there is big, the big money is there, and if a company wants to succeed, that’s the place to do it.”

Do you believe that the biomed field could be the next big thing in the years to come?

About the Author: Ranit Nachum-Halevi is a consultant to real estate companies, and former senior real estate correspondent for The Marker, Haaretz's daily financial supplement. She has been working in Israel's media for more than 15 years. You can reach her at ranit.nh@gmail.com.


If you don't see your comment after publishing it, refresh the page.

Our comments section is intended for meaningful responses and debates in a civilized manner. We ask that you respect the fact that we are a religious Jewish website and avoid inappropriate language at all cost.

If you promote any foreign religions, gods or messiahs, lies about Israel, anti-Semitism, or advocate violence (except against terrorists), your permission to comment may be revoked.

No Responses to “The Israeli Dash to the NASDAQ”

Comments are closed.

SocialTwist Tell-a-Friend

Current Top Story
Chaye Zisel Braun
Funeral for Chaye Zisel Braun Underway [photos]
Latest Indepth Stories
Keeping-Jerusalem

Judea and Samaria (Yesha) have been governed by the IDF and not officially under Israeli sovereignty


n past decades, Oman has struck a diplomatic balance between Saudi Arabia, the West, and Iran.

The Jewish Press endorses the reelection of Gov. Andrew Cuomo. His record as governor these past four years offers eloquent testimony to the experience and vision he has to lead the Empire State for the next four years.

I think Seth Lipsky is amazing, but it just drives home the point that newspapers have a lot of moving parts.

While not all criticism of Israel stemmed from anti-Semitism, Podhoretz contends the level of animosity towards Israel rises exponentially the farther left one moved along the spectrum.

Myth #1: It is easy to be a B’nai Noach. It is extraordinarily hard to be a B’nai Noach.

The question of anti-Semitism in Europe today is truly tied to the issue of immigration.

Polls indicate that the Palestinians are much more against a two state solution than the Israelis.

Turkey and Iran the 2 regional powers surrounding the ISIS conflict gain from a partial ISIS victory

Emigration from Israel is at an all-time low, far lower than immigration to Israel from Europe.

Leon Klinghoffer’s daughters: “‘Klinghoffer’ is justified as ‘a work of art’…This is an outrage.”

Do you seriously think that as you kidnap our children we should medically treat and help yours?

Sometimes collective action against the heinous acts of the majority is not enough. The world should not only support the blockade of Gaza; it must enforce the dismantling of Hamas.

The Arab Spring has challenged Jordan with the task of gradual reform with regard to its monarchy.

More Articles from Ranit Nachum-Halevi
On the beach

Israel’s coastline may be short, but there are still some real estate pearls waiting to be realized, offering cheap alternatives for sea front living. All you have to do is go further from the boundaries of Tel-Aviv and the Dan Block.

Meir Shitrit speaks with the press.

Nave and Golan are advisors helping Meir Sheetrit run for president. As professionals who lead campaigns and shape public opinion, they cite the press as a major factor in this campaign.

Israeli biomedical firms look back on a successful year on Wall Street. Are we bearing witness to “the new tech”?

The romantic skyline of Jerusalem is disappearing. Is Jerusalem on its way to becoming a modern city? Or is it losing its special character?

Government plans to market 12,000 new apartments in Modi’in, where prices haven’t stopped rising in recent years.

It’s a boom: some 100,000 housing units will replace military camps in the high-value center of Israel.

Printed from: http://www.jewishpress.com/indepth/analysis/the-israeli-dash-to-the-nasdaq/2014/05/01/

Scan this QR code to visit this page online: